Scholarlink

<p>Epcoritamab, a CD3 × CD20 bispecific antibody, has been approved as salvage therapy for patients with relapsed/refractory large B-cell lymphoma. However, immunotherapeutic agents have been linked to tumor flare reaction (TFR), which is characterized by rapid tumor proliferation associated with the immune response. This report describes the case of a 71-year-old man with relapsed/refractory diffuse large B-cell lymphoma who developed TFR in the cervical lymph nodes during treatment with epcoritamab. Prompt biopsy upon detection of tumor enlargement led to an accurate diagnosis of TFR and informed therapeutic strategies. Subsequent radiotherapy (RT) effectively controlled local lesions while preserving the systemic immune response, suggesting that RT may be an option to prevent the recurrence and progression of TFR and help to avoid discontinuation of effective therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Histological confirmation and radiotherapy facilitate continuation of epcoritamab in a patient with tumor flare reaction

  • 期刊论文

  • 发表日期：

    2025年3月29日

查看全文
  • Mai Fujita,
  • Sho Okamoto,
  • Kazuki Jinnouchi,
  • Keita Kai,
  • Tatsuya Mihashi,
  • Keisuke Kidoguchi,
  • Kana Kusaba,
  • Haruhiko Sano,
  • Hidekazu Itamura,
  • Mariko Yoshimura,
  • Hiroo Katsuya,
  • Toshihiko Ando,
  • Shinya Kimura

摘要

Epcoritamab, a CD3 × CD20 bispecific antibody, has been approved as salvage therapy for patients with relapsed/refractory large B-cell lymphoma. However, immunotherapeutic agents have been linked to tumor flare reaction (TFR), which is characterized by rapid tumor proliferation associated with the immune response. This report describes the case of a 71-year-old man with relapsed/refractory diffuse large B-cell lymphoma who developed TFR in the cervical lymph nodes during treatment with epcoritamab. Prompt biopsy upon detection of tumor enlargement led to an accurate diagnosis of TFR and informed therapeutic strategies. Subsequent radiotherapy (RT) effectively controlled local lesions while preserving the systemic immune response, suggesting that RT may be an option to prevent the recurrence and progression of TFR and help to avoid discontinuation of effective therapy.